Lonza Publishes 2026 Annual General Meeting Invitation and 2025 Annual and Sustainability Reports 01.04.2026, 06:30 Uhr von EQS News Jetzt kommentieren: 0

Ad hoc announcement pursuant to Art. 53 LR

• Annual General Meeting will take place on 8 May 2026 at the Congress Center in Basel, Switzerland
• Jean-Marc Huët proposed for re-election as Chair of the Board of Directors
• Barbara Richmond, Jürgen Steinemann and Roger Nitsch will not stand for re-election
• All other current members of the Board of Directors are standing for re-election 
• Claudia Süssmuth-Dyckerhoff, Sami Atiya and Stephen Fry are proposed for election as new Board members 
• The proposed dividend is increased to CHF 5.00 per share
• Lonza publishes its 2025 Annual and Sustainability Reports 

Basel, Switzerland, 1 April 2026 – Lonza today announced the publication of its 2025 Annual and Sustainability Reports, as well as its invitation to the 2026 Annual General Meeting (AGM). The event will take place on Friday, 8 May 2026, at 10:00 a.m. CEST, at the Congress Center Messe Basel, Messeplatz 21, 4058 Basel, Switzerland.

2026 Annual General Meeting (AGM)

The Board of Directors proposes the re-election of Jean-Marc Huët as Chair and member of the Board of Directors and the re-election of the following individuals to the Board of Directors, each for a term of office until the completion of the AGM in 2027:

• Juan Andres 
• Eric Drapé 
• Marion Helmes
• Angelica Kohlmann 
• Christoph Mäder 
• David Meline

Barbara Richmond and Jürgen Steinemann will have completed their final terms as Board members at the AGM in May 2026. The Board extends its appreciation for their dedication and significant contributions made. Furthermore, Roger Nitsch has decided not to stand for re-election. Roger has been a member of the Board since 2022 and the Board would like to thank him for his contributions to Lonza.

The Board of Directors proposes the election of three new Board members, each for a term of office until the completion of the AGM in 2027:

• Claudia Süssmuth-Dyckerhoff 
• Sami Atiya
• Stephen Fry

Claudia Süssmuth-Dyckerhoff brings significant international experience in healthcare and life sciences as well as perspectives on the Asian markets. She served on the Board of Directors of Roche Holding AG from 2016 to 2026, during which time she was also a member of the Audit, Corporate Governance and Sustainability Committees. She is also currently a member of the Boards of Prudential Corporation, Clariant AG, Ramsay Health Care and Quest Global. Earlier in her career, she spent two decades in senior roles at McKinsey & Company with a focus on global healthcare and Asia.

Sami Atiya has extensive leadership experience in healthcare, robotics, automation and AI. He spent ten years on the Group Executive Committee of ABB Ltd, overseeing robotics, motion and discrete automation. Before that, he held senior leadership roles at Siemens for more than 15 years, including responsibility for the Computer Tomography and Radiation Oncology business. He currently serves on the Boards of SGS, Cognex and the AI Council of the Port Authority of Singapore.

Stephen Fry brings deep expertise in the biopharmaceutical industry, performance culture and organizational transformation. He spent more than three decades at Eli Lilly and Company, where he held a broad range of international, operational and executive leadership roles, ultimately serving as Executive Vice President and Chief Human Resources Officer (CHRO) from 2011 to 2022. He currently serves on the Board of the University of Indianapolis (US).

Further motions include the re-election and election of the Remuneration Committee members and the approval of the compensation of the Board of Directors and the Executive Committee.

The Board of Directors proposes to increase the dividend by 25% to CHF 5.00 per share at the AGM 2026. Subject to approval, 50% of the dividend will be paid out of the capital contribution reserves, meaning it will be exempt from Swiss withholding tax. 

The AGM invitation can be accessed on the AGM webpage.

2025 Annual and Sustainability Reports

Lonza today published its 2025 Annual Report and 2025 Sustainability Report. PDF versions of the reports can be accessed here.

The Lonza Annual Report 2025 provides an overview of the company’s strategic direction, business structure and key developments across all Business Platforms. It also outlines core elements of Lonza’s operating and financial performance, overall compensation framework and corporate governance.

The Lonza Sustainability Report 2025 highlights the company’s commitments and performance relating to the sustainability priorities most relevant to its business and stakeholders, and is prepared in accordance with the Global Reporting Initiative (GRI) standards.

About Lonza

Lonza is the world’s largest contract development and manufacturing organization (CDMO) dedicated to serving the healthcare industry. Working across five continents, the Lonza global team of approximately 20,000 colleagues works alongside pharma and biotech companies to turn their breakthrough innovations into viable therapies. This enables customers to bring life-saving and life-enhancing treatments to patients worldwide with a combination of cutting-edge science, smart technology and lean manufacturing.

Our company generated sales of CHF 6.5 billion with a CORE EBITDA of CHF 2.1 billion in Full-Year 2025. Find out more at www.lonza.com

Lonza Contact Details

Victoria Morgan
Head of External Communications
Lonza Group Ltd
Tel +41 61 316 2283
victoria.morgan@lonza.com

Daniel Buchta
Head of Investor Relations
Lonza Group Ltd
Tel +41 61 316 2985
daniel.buchta@lonza.com